phrykt

Acadia Pharmaceuticals Inc (ACAD): who owns it and who trades it

As of Nov 16, 2026, ACAD insiders reported 24 open-market sales worth $2.8M and no purchases in the last 12 months, with 32% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark C. Schneyer (CFO), with $1.2M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Acadia Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ACAD

350 funds and institutions reported ACAD shares worth $4.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 25.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Baker Bros. Advisors LP25.1%
BlackRock, Inc.13.1%
State Street Corp5.3%
Vanguard Portfolio Management LLC5.2%
Rtw Investments, LP4.2%
Vanguard Capital Management LLC3.4%
Dimensional Fund Advisors LP2.2%
California State Teachers Retirement System2.0%
Geode Capital Management, LLC2.0%
Palo Alto Investors LP1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP42.91M25.06%$1.1BNo change
BlackRock, Inc.22.52M13.15%$570M+4%
State Street Corp9.08M5.30%$230M+9%
Vanguard Portfolio Management LLC8.84M5.16%$224M+2%
Rtw Investments, LP7.14M4.17%$181MNo change
Vanguard Capital Management LLC5.76M3.37%$146M+2%
Dimensional Fund Advisors LP3.69M2.16%$93.5M+17%
California State Teachers Retirement System3.39M1.98%$134M+2352%
Geode Capital Management, LLC3.36M1.96%$85M-3%
Palo Alto Investors LP2.86M1.67%$72.5M-0%
Goldman Sachs Group Inc2.58M1.51%$65.3M+66%
Qube Research & Technologies Ltd2.45M1.43%$61.9M+157%
Point72 Asset Management, L.P.2.43M1.42%$61.6M-6%
Citadel Advisors LLC2.18M1.27%$55.2M+250%
Pictet Asset Management Holding SA1.98M1.16%$50.1M-2%
Arrowstreet Capital, Limited Partnership1.97M1.15%$49.8M+25%
Marshall Wace, LLP1.76M1.03%$44.7M–
D. E. Shaw & Co., Inc.1.70M0.99%$43M+133%
Braidwell LP1.65M0.96%$41.7M-33%
Norges Bank1.62M0.95%$41.1M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ACAD insiders reported $0 of open-market purchases and $2.8M of sales. 32% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.8M
24 trades, 5 people
Sales under a 10b5-1 plan
32%
Share of sale value
Latest trade
Oct 30, 2026
Filed Oct 30, 2026

Purchases and sales by month

$607K$607KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 30, 2026Mark C. SchneyerCFOSale3,321$20.88$69.3KForm 4
Aug 6, 2026Mark C. SchneyerCFOSale plan5,000$29.00$145KForm 4
Aug 6, 2026Mark C. SchneyerCFOSale plan9,292$29.34$273KForm 4
Aug 5, 2026Mark C. SchneyerCFOSale plan5,849$29.00$170KForm 4
Jul 30, 2026Elizabeth H.Z. ThompsonVice presidentSale50$26.17$1.3KForm 4
Jul 30, 2026Elizabeth H.Z. ThompsonVice presidentSale16,508$26.13$431KForm 4
Jun 26, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale plan11,421$26.08$298KForm 4
May 26, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale5,401$21.18$114KForm 4
May 4, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale1,332$21.79$29KForm 4
May 4, 2026Mark C. SchneyerCFOSale3,506$21.79$76.4KForm 4
Apr 7, 2026Mark C. SchneyerCFOSale2,709$22.20$60.1KForm 4
Apr 7, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale1,030$22.20$22.9KForm 4
Mar 26, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale1,097$21.65$23.8KForm 4
Mar 26, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale12$21.73$261Form 4
Mar 26, 2026Mark C. SchneyerCFOSale3,171$21.65$68.7KForm 4
Mar 26, 2026Mark C. SchneyerCFOSale37$21.72$804Form 4
Mar 25, 2026Adams Catherine OwenCEOSale11,641$21.47$250KForm 4
Mar 25, 2026Jennifer J RhodesVice presidentSale3,844$21.47$82.5KForm 4
Mar 25, 2026Elizabeth H.Z. ThompsonVice presidentSale3,435$21.47$73.7KForm 4
Mar 25, 2026James KiharaPRINCIPAL ACCOUNTING OFFSale833$21.47$17.9KForm 4
Mar 25, 2026Mark C. SchneyerCFOSale4,177$21.47$89.7KForm 4
Feb 9, 2026Jennifer J RhodesVice presidentSale6,950$23.38$162KForm 4
Nov 18, 2025Mark C. SchneyerCFOSale10,262$23.69$243KForm 4
Nov 18, 2025James KiharaPRINCIPAL ACCOUNTING OFFSale4,084$23.69$96.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER–$1.2MOct 30, 2026
James KiharaPRINCIPAL ACCOUNTING OFFICER–$603KJun 26, 2026
Elizabeth H.Z. ThompsonEVP, Head of Research & Dev–$506KJul 30, 2026
Adams Catherine OwenChief Executive Officer, Director–$250KMar 25, 2026
Jennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC–$245KMar 25, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ACAD short interest

Low short interest. 4.8% of ACAD shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went down 27%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.32M ACAD shares were sold short, 4.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.40M shares, buying them all back would take about 5.9 trading days (days to cover).

Shares short, % of all shares

4.81%May 15Oct 307.21%

Days to cover

5.9May 15Oct 3012.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.32M4.81%-9%1.40M5.9
Oct 15, 20269.09M5.28%+10%1.99M4.6
Sep 30, 20268.28M4.80%-14%2.83M2.9
Sep 15, 20269.67M5.61%-1%1.34M7.2
Aug 31, 20269.74M5.65%+3%1.40M6.9
Aug 14, 20269.48M5.50%-12%2.09M4.5
Jul 31, 202610.81M6.27%-2%1.36M8.0
Jul 15, 202611.03M6.44%+1%1.45M7.6
Jun 30, 202610.95M6.40%-7%2.31M4.8
Jun 15, 202611.81M6.90%+0%1.05M11.3
May 29, 202611.75M6.86%+3%1.45M8.1
May 15, 202611.42M6.67%+2%1.95M5.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Acadia Pharmaceuticals company events

Acadia Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 23, 2026LeadershipDeparture Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  3. Sep 24, 2026AnnouncementThe Company announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with ADP. For the primary endpoint of change from baseline in the Scale for the… Filing
  4. Sep 11, 2026AnnouncementThe United States District Court for the Southern District of California preliminarily approved the settlement of the stockholder derivative action captioned Kanner et al. v. Filing
  5. Aug 4, 2026ResultsReleased financial results. Filing
  6. May 29, 2026LeadershipAcadia Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders. Filing
  7. May 6, 2026ResultsReleased financial results. Filing
  8. May 1, 2026LeadershipDeparture Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  9. Mar 5, 2026LeadershipThe board of directors of Acadia Pharmaceuticals Inc., upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jonathan M. Poole to the Board to fill a vacancy and as a member of the Audit Committee of the Board, effective immediately. Filing
  10. Feb 25, 2026ResultsReleased financial results. Filing
  11. Jan 13, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Acadia Pharmaceuticals financials

Famous investors that hold ACAD

7 of the 50 well-known investors we track reported holding ACAD in their latest 13F filing. The largest position is Ken Griffin's, worth $38.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.93M$38.9M0.0%-11%
Steve Cohen · Point72 Asset ManagementQ3 20261.14M$22.9M0.0%-53%
Jim Simons · Renaissance TechnologiesQ3 20261.11M$22.3M0.0%-14%
Israel Englander · Millennium ManagementQ3 2026795,315$16M0.0%+35%
Ken Fisher · Fisher Asset ManagementQ3 2026711,352$14.3M0.0%+2%
Paul Tudor Jones · Tudor Investment CorpQ3 2026105,337$2.1M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 202648,861$985K0.0%-3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ACAD in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G4.4%
Nov 10, 2026STATE STREET CORPORATION13G4.4%

Questions about Acadia Pharmaceuticals Inc (ACAD) stock

Who owns the most ACAD stock?

The largest reported owner of Acadia Pharmaceuticals Inc (ACAD) is Baker Bros. Advisors LP, with 25.1% of the company. In total, 350 funds and institutions reported holding ACAD at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ACAD insiders buying or selling?

In the last 12 months, ACAD insiders reported no open-market purchases and 24 sales worth $2.8M. The latest trade was on Oct 30, 2026. See every trade.

What is the short interest in ACAD?

As of Oct 30, 2026, 8.32M ACAD shares were sold short, 4.8% of the shares outstanding, down 8.5% from the report before. At the average daily volume of 1.40M shares, buying them all back would take about 5.9 trading days (days to cover). See the history.

Which famous investors hold ACAD?

7 of the 50 well-known investors we track reported ACAD in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $38.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.